These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21241731)

  • 1. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
    Kemp TJ; Hildesheim A; Safaeian M; Dauner JG; Pan Y; Porras C; Schiller JT; Lowy DR; Herrero R; Pinto LA
    Vaccine; 2011 Mar; 29(11):2011-4. PubMed ID: 21241731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.
    Bissett SL; Draper E; Myers RE; Godi A; Beddows S
    Vaccine; 2014 Feb; 32(10):1139-46. PubMed ID: 24440205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
    Godi A; Bissett SL; Miller E; Beddows S
    PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
    Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
    Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
    Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
    Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
    Safaeian M; Kemp TJ; Pan DY; Porras C; Rodriguez AC; Schiffman M; Cortes B; Katki H; Wacholder S; Schiller JT; Gonzalez P; Penrose K; Lowy DR; Quint W; van Doorn LJ; Herrero R; Hildesheim A; Pinto LA
    Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
    Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S
    Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.
    Dauner JG; Pan Y; Hildesheim A; Harro C; Pinto LA
    Vaccine; 2010 Jul; 28(33):5407-13. PubMed ID: 20591543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
    Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
    Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
    PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.
    Scherpenisse M; Schepp RM; Mollers M; Meijer CJ; Berbers GA; van der Klis FR
    PLoS One; 2013; 8(9):e74797. PubMed ID: 24058629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
    PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
    Seitz H; Canali E; Ribeiro-Müller L; Pàlfi A; Bolchi A; Tommasino M; Ottonello S; Müller M
    Vaccine; 2014 May; 32(22):2610-7. PubMed ID: 24662712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
    Safaeian M; Porras C; Pan Y; Kreimer A; Schiller JT; Gonzalez P; Lowy DR; Wacholder S; Schiffman M; Rodriguez AC; Herrero R; Kemp T; Shelton G; Quint W; van Doorn LJ; Hildesheim A; Pinto LA;
    Cancer Prev Res (Phila); 2013 Nov; 6(11):1242-50. PubMed ID: 24189371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.